ABOUT
With revolutionizing retinal imaging technology being approved by the FDA plus huge investments, from the likes of Boehringer Ingelheim and Genentech, into the implementation of novel modalities into clinical trials, 2024 is set to be a pivotal year for the retinal imaging field. The opportunities for faster, non-invasive, more accurate and objective measures to drive more drug approvals and reduce clinical trial costs, coupled with state-of-the-art artificial intelligence and retinal imaging data analysis will further propel the drug development fields within ophthalmology, neurology and even cardiovascular disorders.
Designed alongside experts from Ophthalmic R&D from the likes of AbbVie, Boehringer Ingelheim, Genentech, Novartis, Regeneron and Merck, the 2024 agenda tackled preclinical challenges of using clinical imaging tools in NHPs and rodents, discovering new technology and implementing these for better resolution, speed and complexity for retinal vascular diseases, whilst also exploring the expansion of breakthrough AI algorithms within retinal imaging!
What Was New for 2024?
Brand-new speaker faculty with 24+ retinal imaging, data scientists and AI experts from the likes of Boehringer Ingelheim, Genentech, Novartis, Regeneron, AbbVie, Aviceda Therapeutics, and Cleveland Clinic
Robust new content discussing novel imaging modalities, biomarkers and endpoints, as well as improved patient stratification and selection for clinical trials for various retinal diseases including AMD, geographic atrophy, diabetic eye disease, inherited retinal disease and glaucoma
Fresh perspectives from new companies speaking at the 2024 meeting including Ocuphire, ONL Therapeutics, Astellas, Boston Image Reading Centre
Attending Companies Included:
Hear What Your Peers Have to Say:
“Small highly motivated group of scientists from varied background with an intent to positively influence regulatory approval process.”
Senior Principal Scientist, Merck & Co
“Overall event was very well organised with sharp focus and emphasis on few specific areas in retinal diseases clinical trials and treatment. Since it was a small and focused gathering, it was easy to network.”
Chief Technology Officer & Head Of Research & Development, Forus Health
“Very high-quality discussion with industry-wide implications and the willingness for further collaboration.”
Director, Product Development, Abeona Therapeutics